Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study

被引：0
|
作者：
Catherine Reed
Mark Belger
Grazia Dell’Agnello
Kristin Kahle-Wrobleski
Gopalan Sethuraman
Ann Hake
Joel Raskin
David Henley
机构：
[1] Eli Lilly and Company Limited,
[2] Erl Wood Manor,undefined
[3] Eli Lilly Italia,undefined
[4] Eli Lilly and Company,undefined
[5] Indiana University School of Medicine,undefined
来源：
Alzheimer's Research & Therapy | / 10卷
关键词：
Alzheimer’s disease; Randomised controlled trials; Observational studies; Real-world data; Regional differences;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 45 条
  • [1] Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study
    Reed, Catherine
    Belger, Mark
    Dell'Agnello, Grazia
    Kahle-Wrobleski, Kristin
    Sethuraman, Gopalan
    Hake, Ann
    Raskin, Joel
    Henley, David
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [2] Real-world Alzheimer's disease drug treatment-18-month results from an observational study in three European countries (GERAS)
    Reed, C.
    Lebrec, J.
    Dell'agnello, G.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 249 - 249
  • [3] Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study
    Rapp, Thomas
    Andrieu, Sandrine
    Chartier, Florence
    Deberdt, Walter
    Reed, Catherine
    Belger, Mark
    Vellas, Bruno
    [J]. VALUE IN HEALTH, 2018, 21 (03) : 295 - 303
  • [4] Real-world Alzheimer's disease drug treatment-18-month results from an observational study in three European countries (GERAS; encore from 2016 EAN)
    Ueda, K.
    Reed, C.
    Lebrec, J.
    Dell'Agnello, G.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 1026 - 1026
  • [5] Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study
    Kahle-Wrobleski, K.
    Andrews, J. S.
    Belger, M.
    Ye, W.
    Gauthier, S.
    Rentz, D. M.
    Galasko, D.
    [J]. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2017, 4 (02): : 72 - 80
  • [6] Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study
    Lenox-Smith, Alan
    Reed, Catherine
    Lebrec, Jeremie
    Belger, Mark
    Jones, Roy W.
    [J]. BMC GERIATRICS, 2016, 16 : 1 - 10
  • [7] Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study
    Alan Lenox-Smith
    Catherine Reed
    Jeremie Lebrec
    Mark Belger
    Roy W. Jones
    [J]. BMC Geriatrics, 16
  • [8] OBSERVATIONAL STUDY OF RESOURCE USE AND COST OF ALZHEIMER'S DISEASE IN EUROPE (GERAS)-18-MONTH RESULTS FROM THE FRENCH COHORT
    Rapp, T.
    Vellas, B.
    Andrieu, S.
    Chartier, F.
    Baraille, L.
    Belger, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A409 - A409
  • [9] PREDICTORS OF DISEASE PROGRESSION IN MILD ALZHEIMER'S DISEASE DEMENTIA PATIENTS - RESULTS FROM THE GERAS REAL WORLD COHORT AND EXPEDITION TRIALS
    Reed, C.
    Lebrec, J.
    Andrews, J. S.
    Bruno, G.
    Jones, R. W.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A425 - A426
  • [10] EVALUATION OF EUROPEAN ALZHEIMER'S DISEASE REAL-WORLD DATA SOURCES FOR FUTURE PHARMACOECONOMIC OR OUTCOMES RESEARCH
    Lozano-Ortega, G.
    Wang, S.
    Chan, E.
    Bosshard, R.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A82 - A82
12345